Two bleeding disorder treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China. https://t.co/jYTwWsGrU4 ...

Core Insights - Hemab Therapeutics has successfully completed an oversubscribed Series C funding round, raising $157 million to advance therapies for bleeding disorders [1][2] - The funding round was led by Sofinnova Partners, with participation from new investors, a sovereign wealth fund, and existing stakeholders [2] - The company is developing several treatments, including sutacimig, which is set to be the first prophylactic therapy for Glanzmann thrombasthenia [3][4] Funding Details - The Series C funding round raised a total of $157 million, indicating strong investor interest and support [1] - New investors included a sovereign wealth fund and Avoro Capital Advisors, alongside continued backing from existing investors [2] - Joe Anderson from Sofinnova Partners will join the Hemab board as a result of this funding milestone [2] Product Development - Hemab is advancing sutacimig, a bispecific antibody for subcutaneous administration, targeting Glanzmann thrombasthenia [3] - The company plans to initiate a Phase II trial for Factor VII deficiency and advance HMB-002 towards a registration trial [4] - HMB-002 has shown promising Phase I proof of mechanism data, addressing Von Willebrand disease by increasing Von Willebrand Factor and Factor VIII levels [4] Future Plans - Hemab aims to introduce new drug candidates into clinical development, with HMB-003 expected to be announced in the first half of 2026 [5] - The CEO emphasized the importance of investor quality and collaboration with patients to develop innovative treatment options [6][7] - The company believes its expertise in clotting science positions it uniquely to deliver breakthrough therapies [7]